JP2011523560A - Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド - Google Patents

Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド Download PDF

Info

Publication number
JP2011523560A
JP2011523560A JP2011512566A JP2011512566A JP2011523560A JP 2011523560 A JP2011523560 A JP 2011523560A JP 2011512566 A JP2011512566 A JP 2011512566A JP 2011512566 A JP2011512566 A JP 2011512566A JP 2011523560 A JP2011523560 A JP 2011523560A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
peptide
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011512566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523560A5 (enExample
Inventor
ニキル シー． マンシ，
ジェウン バエ，
ケニス シー． アンダーソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of JP2011523560A publication Critical patent/JP2011523560A/ja
Publication of JP2011523560A5 publication Critical patent/JP2011523560A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2011512566A 2008-06-02 2009-06-01 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド Withdrawn JP2011523560A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5818008P 2008-06-02 2008-06-02
US61/058,180 2008-06-02
PCT/US2009/045866 WO2009149021A2 (en) 2008-06-02 2009-06-01 Xbp1, cd138, and cs1 peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014262194A Division JP6085289B2 (ja) 2008-06-02 2014-12-25 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド

Publications (2)

Publication Number Publication Date
JP2011523560A true JP2011523560A (ja) 2011-08-18
JP2011523560A5 JP2011523560A5 (enExample) 2012-07-05

Family

ID=41398806

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2011512566A Withdrawn JP2011523560A (ja) 2008-06-02 2009-06-01 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP2014262194A Active JP6085289B2 (ja) 2008-06-02 2014-12-25 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP2017013407A Active JP6224280B2 (ja) 2008-06-02 2017-01-27 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP2017194380A Active JP6438100B2 (ja) 2008-06-02 2017-10-04 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP2018214477A Active JP6796123B2 (ja) 2008-06-02 2018-11-15 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP2020189192A Active JP7321137B2 (ja) 2008-06-02 2020-11-13 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP2023120931A Pending JP2023134812A (ja) 2008-06-02 2023-07-25 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2014262194A Active JP6085289B2 (ja) 2008-06-02 2014-12-25 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP2017013407A Active JP6224280B2 (ja) 2008-06-02 2017-01-27 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP2017194380A Active JP6438100B2 (ja) 2008-06-02 2017-10-04 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP2018214477A Active JP6796123B2 (ja) 2008-06-02 2018-11-15 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP2020189192A Active JP7321137B2 (ja) 2008-06-02 2020-11-13 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP2023120931A Pending JP2023134812A (ja) 2008-06-02 2023-07-25 Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド

Country Status (6)

Country Link
US (3) US9096681B2 (enExample)
EP (2) EP3384919B1 (enExample)
JP (7) JP2011523560A (enExample)
CN (1) CN102112147B (enExample)
CA (2) CA2726804C (enExample)
WO (1) WO2009149021A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536953A (ja) * 2012-11-05 2015-12-24 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
JP2019059745A (ja) * 2008-06-02 2019-04-18 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2956481B1 (en) 2013-02-15 2020-07-01 The Johns Hopkins University Antigen-specific t cell redirectors
US10752902B2 (en) 2014-09-23 2020-08-25 Board Of Trustees Of Michigan State University Compositions comprising fusion proteins useful for modulating an immune response
US10483541B2 (en) 2016-05-09 2019-11-19 Nichia Corporation Method of producing nickel-cobalt composite hydroxide and method of producing positive electrode active material for non-aqueous electrolyte secondary battery
CN106093393A (zh) * 2016-06-02 2016-11-09 滨州医学院 一种基于XBP1和XBP1s表达水平的检测胃癌组织的试剂盒
US12059463B2 (en) 2017-10-24 2024-08-13 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
CN115040663B (zh) * 2022-06-15 2023-12-12 上海交通大学医学院附属仁济医院 溶质载体家族38成员2在制备多发性骨髓瘤治疗药物中的应用
KR102953721B1 (ko) * 2024-05-16 2026-04-16 주식회사 보노다임 보호캡이 구비된 mems 스위치 및 그 제조 방법
KR102953723B1 (ko) * 2024-05-16 2026-04-16 주식회사 보노다임 다이오드가 구비된 mems 스위치 및 그 제조 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113332A1 (en) * 2001-12-12 2003-06-19 University Of North Texas Health Science Center At Fort Worth Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
JP2007503465A (ja) * 2003-05-08 2007-02-22 ピーディーエル バイオファーマ，インコーポレイティド 抗ｃｓ１抗体の治療的使用
JP2007530675A (ja) * 2004-03-29 2007-11-01 ピーディーエル バイオファーマ，インコーポレイティド 抗ｃｓ１抗体の治療的使用
WO2008019376A2 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
WO2008019378A1 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
EP1359937A4 (en) 2001-02-14 2004-07-28 Genzyme Corp MODIFIED PEPTIDE LIGANDS
US6979720B2 (en) 2002-05-03 2005-12-27 E. I. Du Pont De Nemours And Company manufacture of certain cyclic ester oligomers
WO2005037855A2 (en) 2003-10-17 2005-04-28 Pecos Labs, Inc. T cell epitopes useful in a yersinia pestis vaccine and as diagnostic tools and methods for identifying same
CA2577073C (en) * 2004-09-02 2016-10-11 Wyeth Systems and methods for protein production employing polypeptides functional in unfolded protein response pathway
CA2726804C (en) 2008-06-02 2021-12-28 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113332A1 (en) * 2001-12-12 2003-06-19 University Of North Texas Health Science Center At Fort Worth Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
JP2007503465A (ja) * 2003-05-08 2007-02-22 ピーディーエル バイオファーマ，インコーポレイティド 抗ｃｓ１抗体の治療的使用
JP2007530675A (ja) * 2004-03-29 2007-11-01 ピーディーエル バイオファーマ，インコーポレイティド 抗ｃｓ１抗体の治療的使用
WO2008019376A2 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
WO2008019378A1 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6010014502; Ｊ．　Ｉｍｍｕｎｏｌ． Ｖｏｌ．１６７，　Ｎｏ．１０, 20011115, ｐｐ．５５１７-５５２１ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019059745A (ja) * 2008-06-02 2019-04-18 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP2021054825A (ja) * 2008-06-02 2021-04-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
US11083783B2 (en) 2008-06-02 2021-08-10 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides
JP7321137B2 (ja) 2008-06-02 2023-08-04 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP2015536953A (ja) * 2012-11-05 2015-12-24 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
JP2018172435A (ja) * 2012-11-05 2018-11-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
JP2021152073A (ja) * 2012-11-05 2021-09-30 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
JP7838929B2 (ja) 2012-11-05 2026-04-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
US12616733B2 (en) 2012-11-05 2026-05-05 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions

Also Published As

Publication number Publication date
CA3138282A1 (en) 2009-12-10
EP2300034A4 (en) 2011-11-02
JP2023134812A (ja) 2023-09-27
JP6085289B2 (ja) 2017-02-22
CN102112147A (zh) 2011-06-29
WO2009149021A3 (en) 2010-07-15
JP6796123B2 (ja) 2020-12-02
EP2300034B1 (en) 2018-08-08
JP6438100B2 (ja) 2018-12-12
JP2018023397A (ja) 2018-02-15
US20160008444A1 (en) 2016-01-14
EP3384919B1 (en) 2026-04-01
JP2019059745A (ja) 2019-04-18
CA2726804A1 (en) 2009-12-10
WO2009149021A2 (en) 2009-12-10
JP2017088613A (ja) 2017-05-25
JP6224280B2 (ja) 2017-11-01
CN102112147B (zh) 2014-05-21
EP3384919A1 (en) 2018-10-10
JP2021054825A (ja) 2021-04-08
EP2300034A2 (en) 2011-03-30
US20220031821A1 (en) 2022-02-03
CA2726804C (en) 2021-12-28
JP2015063559A (ja) 2015-04-09
US11083783B2 (en) 2021-08-10
US20110159021A1 (en) 2011-06-30
JP7321137B2 (ja) 2023-08-04
US9096681B2 (en) 2015-08-04

Similar Documents

Publication Publication Date Title
JP6438100B2 (ja) Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP7838929B2 (ja) Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
HK1215531B (en) The use of compositions of xbp1, cd138, and cs1 peptides for preparing medicament

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140922

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150303

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150304